-
Abstract: The incidence of peripheral neuropathy caused by multiple myeloma is increasing in recent years.In addition to primary diseases,chemotherapy drug is one of the important causes of the peripheral neuropathy,which is a challenge of treatment.Peripheral neuropathy includes sensory nerve,motor nerve and autonomic neuropathy,corresponding to clinical symptoms respectively.At present,there is no widely accepted diagnostic and treatment standard for peripheral neuropathy in multiple myeloma.And the severity of neuropathy can be evaluated and monitored according to varieties of assessments.Treatment mainly includes the use of supplements,analgesics and physical therapies.This review presents the progress in different assessments,pathogenesis,clinical presentation and treatment of peripheral neuropathy in multiple myeloma.
-
Key words:
- multiple myeloma /
- peripheral neuropathy /
- bortezomib /
- thalidomide
-
-
[1] Delforge M, Bladé J, Dimopoulos MA, et al.Treatment-related peripheral neuropathy in multiple myeloma:the challenge continues[J].Lancet Oncol, 2010, 11:1086-1095.
[2] Mccullough KB, Hobbs MA, Abeykoon JP, et al.Common adverse effects of novel therapies for multiple myeloma (MM) and their management strategies[J].Curr Hematol Malig Rep, 2018, 13:114-124.
[3] 中国医师协会血液科医师分会多发性骨髓瘤专业委员会.多发性骨髓瘤周围神经病变诊疗中国专家共识(2015年)[J].中华内科杂志, 2015, 54(9):603-606.
[4] Morawska M, Grzasko N, Kostyra M, et al.Therapy-related peripheral neuropathboy in multiple myeloma patients[J].Hematol Oncol, 2015, 33:113-119.
[5] 韩秀华, 赵兰, 张飞飞, 等.低剂量沙利度胺联合化疗治疗多发性骨髓瘤周围神经病变的发生情况[J].临床血液学杂志, 2017, 30(11):870-872.
[6] 孟激光, 王凡, 韩志海.多发性骨髓瘤伴发周围神经病变机制的研究进展[J].医学综述, 2016, 22(24):4843-4847.
[7] Luczkowska K, Litwinska Z.Pathophysiology of drug-induce peripheral neuropathy in patients with multiple myeloma[J/OL].www.jpp.krakow.pl, 2018-02-02.
[8] Mahmoudpour SH, Bandapalli OR, da Silva Filho MI, et al.Chemotherapy-induced peripheral neuropathy:evidence from genome-wide association studies and replication within multiple myeloma patients[J].BMC Cancer, 2018, 18:820.
[9] National Institutes of Health, National Cancer Institute.Common Terminology Criteria for Adverse Events (CTCAE)v5.0[EB/OL].https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf, 2017-11-27.
[10] Cheng HL, Molassiotis A.Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx)[J].Asia Pac J Clin Oncol, 2019, 15:56-62.
[11] Chung T, Prasad K, Lloyd TE.Peripheral neuropathy:clinical and electrophysiological considerations[J].Neuroimaging Clin N Am, 2014, 24:49-65.
[12] Alberti P, Rossi E, Cornblath DR, et al.Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity:two sides of the same coin[J].Ann Oncol, 2016, 25:257-264.
[13] Lakshman A, Modi M, Prakash G, et al.Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction[J].Clin Lymphoma Myeloma Leuk, 2017, 17:513-519.
[14] Mols F, Lv PF, Vreugdenhil G, et al.Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population[J].Eur J Cancer, 2016, 69:28-38.
[15] Smith EML, Banerjee T.Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data[J].Cancer Nurs.2018 Apr 12.doi:10.1097/NCC.0000000000000596.[Epub ahead of print].
[16] Mangiacavalli S, Cocito F, Ferretti VV, et al.The advantages of switch to subcutaneous bortezomib in the real life[J].Leuk Lymphoma, 2017, 59:1-3.
[17] Kumar SK, Laubach JP, Giove TJ, et al.Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma[J].Br J Haematol, 2017, 178:756-763.
[18] Zhi WI, Ingram E, Li SQ, et al.Acupuncture for bortezomib-induced peripheral neuropathy:not just for pain[J].Integr Cancer Ther, 2018, 17:1079-1086.
[19] Han X, Wang L, Shi H, et al.Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma[J].BMC Cancer, 2017, 17:40.
-
计量
- 文章访问数: 404
- PDF下载数: 224
- 施引文献: 0
下载: